Skip to content

A multicenter randomized controlled trial of new-generation microwave ablation and radiofrequency ablation for hepatocellular carcinoma

A multicenter randomized controlled trial of new-generation microwave ablation and radiofrequency ablation for hepatocellular carcinoma - A multicenter RCT of new-generation MWA and RFA for HCC

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000035442
Enrollment
210
Registered
2019-01-04
Start date
2018-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

radiofrequency ablation new-generation microwave ablation

Sponsors

Juntendo University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patient at the age of 20 to 100 when the informed consent was obtained 2. Patient with histopathologically confirmed carcinoma or tumors showing characteristic imaging features of hepatocellular carcinoma 3. Tumors were unresectable or patient declined surgery 4. Three or fewer tumors, each 3 cm or less in diameter, or a solitary lesion, 5 cm or less in diameter (Patients with both primary and recurrent tumors were included. Patients with local tumor progression were excluded) 5. No extrahepatic metastasis or vascular invasion 6. Patient with written informed consent

Exclusion criteria

Exclusion criteria: 1. Patient with prothrombin activity of 50% or less. Patient with low platelet count that cannot be corrected by lusutrombopag or platelet transfusion 2. Patient with refractory ascites and at high risk of peritoneal bleeding 3. Patient with enterobiliary reflux 4. Contrast-enhanced CT cannot be performed because of renal dysfunction (creatinine of 2 mg/dL or more) or allergic adverse reactions to iodine contrast agents 5. Child-Pugh class C 6. ASA's (American Society of Anesthesiologists) physical score 3 or above 7. Patient who cannot accept necessary treatments, such as blood transfusion, because of religious reasons and others 8. Patient who cannot follow medical instructions because of dementia and others 9. Patient with tumors not visualized by ultrasonography or not accessible 10. Patient with adhesion between tumors and the gastrointestinal tract which may cause GI tract penetration or perforation 11.Patient with tumors adjacent to the major Glisson's capsule which may cause serious biliary injury or hepatic infarction 12.Patient not considered eligible to participate in this study by the attending doctor due to various reasons

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the technical success rate evaluated by the CT scan taken after the first session of new-generation microwave ablation or radiofrequency ablation The secondary endpoints are 1) complete ablation ratio of tumors after the final session of of new-generation microwave ablation or radiofrequency ablation, 2) the number of sessions until completion of the treatment, and adverse event ratio.

Countries

Japan

Contacts

Public ContactSHUICHIRO SHIINA

Juntendo University Department of Gastroenterology

ivo@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026